Abstract
Maintaining mitochondrial health is emerging as a keystone in aging and associated diseases. The selective degradation of mitochondria by mitophagy is of particular importance in keeping a pristine mitochondrial pool. Indeed, inherited monogenic diseases with defects in mitophagy display complex multisystem pathologies but particularly progressive neurodegeneration. Fortunately, therapies are being developed that target mitophagy allowing new hope for treatments for previously incurable diseases. Herein, we describe mitophagy and associated diseases, coin the term mitophaging and describe new small molecule interventions that target different steps in the mitophagic pathway. Consequently, several age-associated diseases may be treated by targeting mitophagy.
Mitochondrial Integrity Defines Organismal Health
Mitochondria, the powerhouses of eukaryotic cells, are the key organelles for energy production allowing organismal growth and survival. Besides serving as adenosine triphosphate generators, mitochondria act as signaling hubs for programmed cell death, regulate calcium homeostasis and are required for cholesterol, nucleotide and amino acid synthesis (Sun et al., 2016). To fulfil their broad range of biological roles, mitochondria contain more than 1,000 proteins that localize and function in four specialized compartments, the outer membrane, the inner membrane, the intermembrane space and the matrix. The minority of mitochondrial proteins are encoded by the circular mitochondrial genome, whereas the vast majority is encoded in the nuclear genome. However, mutations in both genomes can cause a heterogeneous group of disorders, known as mitochondrial diseases, which are characterized by severe metabolic and neurological defects. Due to their highly variable clinical features, the prevalence of mitochondrial diseases has likely been underestimated (Haas et al., 2007; Wallace, 2018). Nevertheless, advances in next generation sequencing technologies have simplified the clinical diagnosis and enabled molecular characterization of so far undescribed mitochondrial diseases (Calvo et al., 2012; Cui et al., 2013; Legati et al., 2016). Notably, computational approaches relying on phenotypic description of mitochondrial diseases can help to characterize new mitochondrial diseases of previously unknown pathogenesis (Scheibye-Knudsen et al., 2013).
Increased evidence indicates that mitochondrial integrity is disrupted during the aging process and contributes to the pathogenesis of age-related disorders in humans (Kauppila et al., 2017; Youle, 2019). In line with this, mice that carry a defective proof-reading mitochondrial DNA polymerase gamma show an accelerated aging phenotype that may be driven by the accumulation of mutations in the mitochondrial DNA (mtDNA) (Trifunovic et al., 2004). The described correlation between levels of mtDNA deletions in human brain and aging as well as the association between mtDNA haplogroups and diseases, further supports the direct influence of mitochondria on health- and lifespan in organisms (Cortopassi and Arnheim, 1990; Corral-Debrinski et al., 1992; Hudson et al., 2014; Wallace, 2015). Indeed, dysfunctional degradation of mitochondria through the process of mitophagy is increasingly associated with degenerative diseases and aging, a phenomenon we call mitophaging. Evidently, the maintenance of functional mitochondria is necessary to sustain cellular homeostasis and organismal health.
Mitochondrial Quality Control Mechanisms
Mitochondria have evolved multiple mechanisms ensuring mitochondrial quality. For instance, mitochondrial chaperones and proteases are constantly preventing the accumulation of misfolded and aggregated proteins by monitoring proteostasis through the mitochondrial unfolded protein stress response (UPRmt) (Melber and Haynes, 2018), a mechanism that has been shown to be critical for longevity in mammals (Houtkooper et al., 2013; Mouchiroud et al., 2013). Further, mitochondria are dynamic organelles existing in large tubular and highly dynamic networks that constantly undergo fission and fusion processes, thereby leading to the dilution of non-functional mitochondria (Youle and van der Bliek, 2012).
Nevertheless, autophagy is the only known pathway that mediates the turnover of whole mitochondria to avoid cellular damage and apoptosis. The degradation process is mediated by a double-membrane vesicle, known as the autophagosome, and it was first observed in mammalian cells by electron microscopy (De Duve and Wattiaux, 1966). For a long time, autophagy was considered a non-selective bulk degradation pathway, however, when the yeast mitochondrial protein Uth1p was found to be involved in the selective degradation of mitochondria (Kissová et al., 2004), the term “mitophagy” was subsequently introduced (Lemasters, 2005).
Herein, we discuss the role of mitophagy in impacting human disease development and the aging process itself. Further, interventions that target mitophagy will be discussed that may provide a promising strategy for the treatment of a broad spectrum of diseases.
What Is Mitophagy?
The process of mitophagy can act either as a response to various stress stimuli including nutrient starvation and oxidative stress or as a programmed removal of mitochondria (Palikaras et al., 2018; Pickles et al., 2018). Different pathways are known to regulate mitophagy, the best-studied pathway is mediated by the phosphatase and tensin homologue (PTEN)-induced putative kinase 1 (PINK1) and the E3-ubiquitin ligase Parkin (Figure 1A). Mutations in both genes encoding PINK1 and Parkin (PARK2), have been reported to cause autosomal recessive forms of Parkinson’s Disease (PD) (Kitada et al., 1998; Valente et al., 2004). Under un-stressed conditions, PINK1 is imported via the translocase of the outer membrane and translocase of the inner membrane (TOM/TIM) complex in a membrane potential dependent manner into mitochondria, leading to proteolytic cleavage of PINK1 (Jin et al., 2010; Deas et al., 2011; Meissner et al., 2011). The N-terminal truncated PINK1 is subsequently released to the cytosol, and degraded by the proteasome (Yamano and Youle, 2013). Loss of mitochondrial membrane potential disrupts the transport of PINK1 across the mitochondrial membrane leading to the accumulation of uncleaved PINK1 at the outer mitochondrial membrane. Subsequently, PINK1 regulates the recruitment and activation of the cytosolic Parkin via direct phosphorylation of the Parkin Ub-like (UBL) domain or via the phosphorylation of ubiquitin (Kondapalli et al., 2012; Shiba-Fukushima et al., 2012; Iguchi et al., 2013; Kane et al., 2014; Kazlauskaite et al., 2014; Koyano et al., 2014; Ordureau et al., 2014; Wauer et al., 2015). Once activated, Parkin drives the ubiquitination of multiple substrates, which leads to a positive feed forward mechanism through the generation of additional substrates for Pink1 (Ordureau et al., 2014).
FIGURE 1
In recent years, several substrates, in particular mitochondrial outer membrane proteins and autophagy receptors, have been identified to be ubiquitinated by the PINK1/Parkin-mediated signaling pathway (Sarraf et al., 2013). For instance, the mitochondrial fusion proteins mitofusin 1 and 2 (Mfn1 and Mfn2) are degraded in a PINK1/parkin dependent manner to make mitochondria accessible for degradation and to prevent fusion of damaged mitochondria with the healthy network (Gegg et al., 2010; Tanaka et al., 2010). However, conditional double-knockout of Mfn1 and Mfn2 in mice leads to mitochondrial dysfunction and, in line with this, Mfn2-depleted cardiomyocytes are deficient in Parkin recruitment to the mitochondrial outer membrane (Chen et al., 2011; Chen and Dorn, 2013). A similar priming function of mitochondria has been described for other mitochondrial proteins such as Miro1 and VDAC1 (Geisler et al., 2010; Wang et al., 2011; Sun et al., 2012; Safiulina et al., 2019). Recently, the apoptotic protein BAK has been identified as a Parkin target, further connecting Parkin-mediated mitophagy to the regulation of cellular apoptosis (Bernardini et al., 2019). The ubiquitination events driven by PINK1 and Parkin enable the recruitment of autophagy substrate receptors to the mitochondrial membrane including p62, Optineurin and NDP52, thereby promoting the engulfment of mitochondria by autophagosomes (Geisler et al., 2010; Wong and Holzbaur, 2014; Lazarou et al., 2015).
Notably, transcriptional regulation is a crucial process for functional PINK1-Parkin-mediated mitophagy. For instance, PINK1-Parkin-mediated mitophagy induction upon cellular stress such as through reactive oxygen species or ethanol exposure leads to the nuclear translocation of several transcription factors, including the transcription factor EB (TFEB) and the nuclear respiratory factors (NRFs), controlling the expression of mitochondrial, autophagy and lysosomal genes (Nezich et al., 2015; Ivankovic et al., 2016; Eid et al., 2019). Parkin expression itself has also been shown to be tightly controlled by stress pathways such as the unfolded protein response pathway and its activating transcription factor 4 (ATF4) (Bouman et al., 2011). Altogether, this highlights the great number of potential therapeutic avenues to target the PINK1-Parkin signaling pathway.
Pink1/Parkin-independent mitophagy pathways mainly rely on receptor proteins which mediate the recruitment of LC3/GABARAPs for the removal of mitochondria (Figure 1B). For instance, the BCL2-related protein NIX (also known as BNIP3L) mediates mitophagy in mammals during reticulocyte differentiation, a process that requires the elimination of mitochondria (Schweers et al., 2007; Sandoval et al., 2008; Novak et al., 2010). In line with this, NIX knockout mice develop anemia and reticulocytosis (Schweers et al., 2007; Sandoval et al., 2008). The interaction of NIX with LC3 protein members is mediated via the LC3-interacting (LIR) motif, however, re-expression of LIR-mutant NIX in NIX deficient reticulocytes partially rescued the observed phenotype, indicating LC3-independent or even autophagy-independent mechanisms for mitochondrial clearance in reticulocyte differentiation (Novak et al., 2010). Another LIR-motif containing protein, FUNDC1, regulates mitophagy under hypoxic conditions by promoting mitochondrial fission (Liu et al., 2012; Chen et al., 2016). During cardiac progenitor cell differentiation, FUNDC1 and NIX, but not Pink1 and Parkin, are upregulated to maintain a functional mitochondrial network (Lampert et al., 2019). Mitophagy is therefore also regulated in a lineage dependent fashion.
Localized removal of mitochondrial subdomains can be mediated by piecemeal mitophagy or mitochondrial-derived vesicles (Figure 1C). Mitochondrial-derived vesicle formation is thought to be dependent on PINK1/Parkin but independent of the canonical autophagy machinery (Soubannier et al., 2012; McLelland et al., 2014). Whereas, the accumulation of misfolded mitochondrial protein aggregates leads to localized recruitment of Parkin and autophagy proteins, thereby facilitating the degradation of mitochondrial subdomains (Burman et al., 2017). A PINK1/Parkin-independent piecemeal mitophagy has been recently reported that drives LC3C- and p62-mediated degradation of mitochondrial subregions (Le Guerroué et al., 2017). However, the protein machinery for these mitochondrial degradation pathways may overlap with the classic mitophagy pathways as well as their physiological relevance needs to be further investigated.
Mitophaging
A decline in mitochondrial function is a hallmark of the aging process and is connected to other aging hallmarks such as telomere dysfunction, genome instability and cellular senescence. However, it remains largely unclear how these processes are interconnected and finally provoke disruption of the cellular and tissue integrity (López-Otín et al., 2013). There is accumulating evidence that mitophagy impacts health- and lifespan in different model organisms. Using a transgenic mouse strain that expresses the fluorescent mitophagy reporter mt-Keima, a decreased mitophagy level was observed in the hippocampal dentate gyrus in 21-month old mice compared to 3-month old mice (Sun et al., 2015). A decline in mitophagy was also observed in aged mouse hearts, in line with this, altered mitophagy has been shown to influence different cardiac pathologies (Hoshino et al., 2013; Bravo-San Pedro et al., 2017). Other tissues that contribute to aging phenotypes are also characterized by defective mitophagy, as shown recently for aged skeletal muscle satellite cells isolated from humans or mice (García-Prat et al., 2016). Notably, decreased expression of mitophagy genes was observed in the skeletal muscle of physically inactive elderly women (Drummond et al., 2014).
The effect of changes in mitophagy on health- and lifespan has been particularly demonstrated by using the model organisms C. elegans and D. melanogaster. Several genetic studies in D. melanogaster revealed that the overexpression of mitochondrial and mitophagy genes leads to increased health- and/or lifespan. For instance, the overexpression of the mitochondrial fission protein dynamin-related protein 1 (DRP1) increased the lifespan along with a prolonged healthspan in flies (Rana et al., 2017). The importance of mitochondrial fission on drosophila lifespan was further demonstrated by the observation that lifespan extension caused by the overexpression of p62 was abrogated in DRP1 mutant flies (Aparicio et al., 2019). Lifespan extension in flies was also observed after overexpression of Parkin and Pink1, whereby, Parkin overexpression counteracted increased Mfn2 levels, which can be observed during aging (Todd and Staveley, 2012; Rana et al., 2013). These findings are consistent with studies in C. elegans, where mitophagy has been shown to contribute to lifespan regulation (Palikaras et al., 2015; Schiavi et al., 2015). Evidently, there is substantial data supporting a role of declining mitophagy, mitophaging, in aging.
What Happens When Mitophagy Goes Wrong?
Impaired mitophagy contributes to the pathogenesis of several human diseases, in particular to age-related sporadic disorders, such as Parkinson’s disease, Alzheimer’s disease, cardiomyopathies and cancer (Bernardini et al., 2017; Fivenson et al., 2017; Levine and Kroemer, 2019). While these observations yield interesting correlations between certain disease states and alterations in mitophagy it is difficult to deduct causation. Here, monogenic diseases with specific defects in mitophagy may give us mechanistic understanding of pathogenesis and biology (Table 1). Thus, monogenic disorders may provide valuable tools for studying molecular pathomechanisms that are driven by defective mitophagy. To explore the clinical phenotype of autophagy diseases, we identified the clinical descriptions in the literature of all the diseases in Table 1 and performed hierarchical clustering based on the prevalence of those features (Figure 2A; Scheibye-Knudsen et al., 2013; Andreassen et al., 2019). Although the clustering did connect clinically similar diseases (such as Charcot–Marie–Tooth 2A2 and 2B), it became immediately apparent that there is no good correlation between clinical outcome and the putative molecular function of the gene responsible for the disease. Indeed, principal component analysis also did not show any obvious separation of clinical groups based on proposed molecular functions (Figure 2B). This suggests that our knowledge of the pathogeneses of most of these disorders is quite limited. Nevertheless, when looking at the average prevalence of clinical features across all aging diseases there was a considerable overrepresentation of neurological features suggesting that defects in autophagy often leads to brain disease (Figure 2C). More specifically, the phenotype in the autophagy disorders show significant overlap with what is seen in mitochondrial diseases indicating that mitochondrial dysfunction may be driving diseases in many autophagy-related disorders ranging from lysosomal diseases to bonafide mitophagy deficiencies (Figures 2C,D). In the following we will examine a few key examples of these disorders.
TABLE 1
| Disease | Gene | Protein function | Symptoms | References |
| Amyotrophic lateral sclerosis | OPTN (AD) | Autophagy receptor | Motor neuron degeneration | Weil et al., 2018 |
| Alzheimer’s disease | APP (AD) | Transmembrane protein | Dementia | Fang et al., 2019 |
| Ataxia-telangiectasia | ATM (AR) | DNA-damage response | Cerebellar degeneration, Telangiectasia, Radiosensitivity | Fang et al., 2016 |
| Autosomal dominant optic atrophy | OPA1 (AD) | Mitochondrial fusion protein | Optic atrophy | White et al., 2009; Liao et al., 2017 |
| Barth syndrome | TAZ (XLR) | Mitochondrial protein | 3-Methylglutaconic aciduria, Cardiomyopathy, Neutropenia; Muscle weakness | Hsu et al., 2015 |
| Charcot–Marie–Tooth disease | MFN2, RAB7 (AD, AR) | Mitochondrial fusion protein, endolysosomal protein | Neuropathy, Muscle weakness | Yamano et al., 2014; Rizzo et al., 2016 |
| Charlevoix-Saguenay spastic ataxia | SACS (AR)* | Co-chaperone | Cerebellar degeneration, Neuropathy, Spasticity | Bradshaw et al., 2016; Morani et al., 2019 |
| Cockayne syndrome | ERCC6 (AR) | DNA damage repair | Cerebellar degeneration, Short stature, Sun sensitivity | Scheibye-Knudsen et al., 2012 |
| Danon disease | LAMP2 (XLD) | Autolysosome formation | Cardiomyopathy, Developmental delay, Myopathy | Tanaka et al., 2000; Hashem et al., 2017 |
| Fabry disease | GLA (XL) | Lysosomal enzyme | Nephropathy, Cardiomyopathy, Hearing loss, Neuorpathy | Chévrier et al., 2010; Ivanova et al., 2019 |
| Fanconi anemia | FANCC (AR) | DNA damage repair | Short stature, Anemia, Skin pigmentation changes, Osteopenia | Sumpter et al., 2016 |
| Frontotemporal dementia and/or amyotrophic lateral sclerosis | TBK1, SQSTM1 (AD) | Serine/threonine protein kinase, autophagy receptor | Dementia, Motor neuron degeneration, | Geisler et al., 2010; Richter et al., 2016 |
| Gaucher disease | GBA1 (AR) | Lysosomal enzyme | Hepatosplenomegali, Pancytopenia, Gaucher cells | Osellame et al., 2013 |
| Intellectual developmental disorder with short stature and variable skeletal anomalies | WIPI2 (AR) | Autophagosome formation | Mental retardation, Cerebral atrophy, Short stature | Zachari et al., 2019 |
| Krabbe disease | GALC (AR)* | Lysosomal enzyme | Spasticity, Leukodystrophy, Myoclonus | Del Grosso et al., 2019 |
| Lafora disease | EPM2A (AR) | Glycogen synthesis | Seizures, Mental retardation | Lahuerta et al., 2018 |
| Microcephaly 18 | WDFY3 (AD) | Selective autophagy, aggrephagy | Cognitive deficits, Microcephaly | Napoli et al., 2018 |
| MRXST | HUWE1 (XL) | E3-ubiquitin protein ligase | Mental retardation, Macrocephaly, Macroorchidism, Seizures | Di Rita et al., 2018 |
| Mucolipidosis II | GNPTAB (AR)* | Lysosomal enzyme | Developmental delay, Short stature, Cardiomegaly, Dysostosis multiplex | Otomo et al., 2009 |
| Multiple sulfatase deficiency | SUMF1 (AR)* | ER-resident enzyme | Cerebellar degeneration, Mental retardation, Hepatosplenomegaly | Settembre et al., 2008 |
| NADGP | SQSTM1 (AR) | Autophagy receptor | Cerebellar degeneration, Mental retardation, Vertical gaze palsy, Dystonia | Geisler et al., 2010 |
| NBIA5 | WDR45 (XLD)* | Autophagosome formation | Cerebellar degeneration, Developmental delay, Brain iron accumulation, Dystonia | Saitsu et al., 2013 |
| NEDSBAS | WDR45B (AR)* | Autophagosome formation | Seizures, Developmental delay, Spasticity, Cerebral atrophy | Bakula et al., 2017; Suleiman et al., 2018 |
| Neuronal Ceroid Lipofuscinosis | PPT1 (AR)* | Lysosomal enzyme | Mental retardation, Seizures, Cerebellar degeneration | Mukherjee et al., 2019 |
| Niemann-Pick disease | NPC1 (AR)* | Lysosomal protein | Seizures, Jaundice, Hepatosplenomegaly, Mental retardation | Pacheco et al., 2007 |
| Parkinson’s disease | LRRK2, PARK2, PARK6 (AD) | Mitochondrial proteins | Bradykinesia, Rigidity, Tremor, Dementia | Ryan et al., 2015 |
| Pompe disease | GAA (AR)* | Lysosomal enzyme | Muscle weakness, Cardiomyopathy, Hypotonia | Raben et al., 2012 |
| Spastic paraplegia 15 | ZFYVE26 (AR)* | Autophagosome formation | Spasticity, Hyperactive reflexes, Mental retardation | Vantaggiato et al., 2013; Denton et al., 2018 |
| Spastic paraplegia 49 | TECPR2 (AR)* | LC3/GABARAP binding protein | Developmental delay, Spasticity, Dysmorphism, Microcephaly, Hypotonia, Short stature | Oz-Levi et al., 2012 |
| Spinocerebellar ataxia 25 | ATG5 (AR) | Autophagosome formation | Developmental delay, Cerebellar degeneration, Mental retardation | Sun et al., 2015 |
| Spinocerebellar ataxia 4 | VPS13D (AR) | Lysosomal enzyme | Hyperactive reflexes, Muscle atrophy, Cerebeller degeneration | Anding et al., 2018 |
| Vici syndrome | EPG5 (AR)* | Autolysosome formation | Cataracts, Cardiomyopathy, Developmental delay, Hypotonia, Immune deficiency, Corpus callosum agenesis | Cullup et al., 2013 |
| Wolfram syndrome | WFS1 (AR) | Calcium homeostasis | Diabetes mellitus type 1, Optic atrophy, Hearing loss, Diabetes insipidus | Cagalinec et al., 2016 |
| Xeroderma pigmentosum group A | XPA (AR) | DNA damage repair | Sun sensitivity, Cerebellar degeneration, Cancer, Neuropathy | Fang et al., 2014 |
| Zellweger syndrome | PEX13 (AR) | Peroxisome biogenesis | Developmental delay, Dysmorphism, Hepatosplenomegaly, Seizures | Lee et al., 2017 |
Examples of autophagy/mitophagy-related monogenic disorders.
For genes that are marked with an asterisk the function in mitophagy remains largely unknown, however, defects in autophagy and mitochondrial dysfunction have been reported. Abbreviations: AD, autosomal dominant; AR, autosomal-recessive; XLR, X-linked recessive; XLD, X-linked dominant.
FIGURE 2
Defects in the Autophagic Machinery
To date, only a few monogenic diseases caused by single mutations in the autophagy core machinery have been reported. One of them, spinocerebellar ataxia-25 (SCAR25), is caused by a mutation in the autophagy-related 5 gene (ATG5), encoding a protein that is part of the ATG12-ATG5-ATG16L1 complex, which facilitates LC3/GABARAP conjugation (Mizushima, 2020). So far, two siblings have been identified with SCAR25, presenting with clinical symptoms such as truncal ataxia and intellectual disability (Kim et al., 2016). In line with the neurological phenotypes, a neuron-specific knockout of ATG5 in mice causes neuronal degeneration, by contrast, a complete ATG5 knockout is neonatal lethal (Kuma et al., 2004; Hara et al., 2006). Ataxia is a common feature of many mitochondrial disorders (Scheibye-Knudsen et al., 2013), however, mitochondrial viability in SCAR25 has not been investigated so far. Thus, the contribution of mitochondrial defects to the reported clinical features in SCAR25 remains speculative, since ATG5-independent mitophagy pathways have been reported (Honda et al., 2014; Hirota et al., 2015).
Mutations in members of the human WD-repeat protein interacting with phosphoinositides (WIPI) family are known to cause neurological deficits. The WIPI protein family consists of four members, WIPI1–WIPI4, that contribute to the early steps of autophagosome formation (Proikas-Cezanne et al., 2004). The family member WIPI2 localizes in a phosphatidylinositol 3-phosphate-dependent manner to the autophagosomal membrane, where it facilitates ATG16L1 recruitment and LC3 lipidation (Dooley et al., 2014; Bakula et al., 2017). Recently, patients with mutations in the WIPI2 gene have been described with multisystemic clinical features, primarily, neurological and skeletal deficiencies that are characterized by severe mental retardation and short stature (Jelani et al., 2019). Notably, WIPI2 overexpression prevents age-related autophagy decline in dorsal root ganglion neurons (Stavoe et al., 2019). Patients with mutations in the genes WIPI3 (WDR45B) or WIPI4 (WDR45) show severe and progressive neurodegenerative phenotypes (Haack et al., 2012; Hayflick et al., 2013; Saitsu et al., 2013; Suleiman et al., 2018). Notably, WIPI4 mutations result in degeneration of the substantia nigra, a target area of the brain affected in Parkinson’s disease (Mann et al., 1992). In line with these observations, WIPI3 or WIPI4 knockout mice show neurological defects, possibly caused by defective neuronal autophagy (Zhao et al., 2015; Ji et al., 2019). WIPI3 and −4 knockout mice display mitochondrial dysmorphology, which was also evident in WIPI4 mutant human fibroblast cells (Zhao et al., 2015; Seibler et al., 2018; Ji et al., 2019). The patient phenotypes caused by mutations in the WIPI genes highlight the importance of the WIPI protein members for neuronal function, however, the contribution of WIPI-mediated clearance of mitochondria in neurodegeneration remains unclear.
Deficiency in the late stage of autophagy is observed in the autosomal recessive neurological disorder, Vici syndrome. The disease is caused by mutations in the ectopic P-granules autophagy protein 5 gene (EPG5), encoding for a Rab7 effector protein that is required for the fusion of late autophagosomes with lysosomes (Cullup et al., 2013; Wang et al., 2016). The disease is characterized by multisystemic defects that show some overlap with mitochondrial diseases, such as agenesis of corpus callosum, cardiomyopathy, immunodeficiency, cataracts and hypopigmentation (Cullup et al., 2013). Mitochondria with abnormal shape and distribution were observed in muscle tissue biopsies from patients with Vici syndrome or EPG5 knockout mice (Cullup et al., 2013; Zhao et al., 2013). The importance of EPG5 in mitochondrial homeostasis was further highlighted by a study showing deficient mitochondrial clearance during spermatogenesis in an EPG5-deficient medaka fish line (Herpin et al., 2015).
Cargo recognition and degradation in selective autophagy is mediated by autophagy receptor proteins, such as optineurin and p62. Both proteins are associated with the progressive neurological disorder amyotrophic lateral sclerosis (ALS), which is primarily caused by loss of motor neurons (Maruyama et al., 2010; Fecto et al., 2011). Around 10% of ALS cases are caused by inherited single gene mutations and frequently show comorbidity with frontotemporal dementia (FTD). Interestingly, optineurin and p62 are phosphorylated by tank-binding kinase 1 (TBK1), a serine/threonine kinase that has also been implicated in ALS-FTD disease development (Cirulli et al., 2015; Freischmidt et al., 2015; Pottier et al., 2015). Thus, there is a striking correlation with mutations in multiple mitophagy players leading to ALS.
Defects in Mitochondrial Quality Control
Proteins involved in the regulation of mitochondrial quality control are essential modulators of mitophagy, consequently, understanding their molecular mechanisms may give important insights into the consequences of impaired mitophagy. In recent years, mitochondrial dysfunction has been extensively discussed as an important contributor to neurodegeneration in familial Parkinson’s disease, as well as in idiopathic forms (Bose and Beal, 2016). Early onset recessive familial Parkinson’s disease can be caused by mutations in the genes Park2 (Parkin), Park6 (Pink1), or Park7 (DJ-1). All three proteins localize to mitochondria and loss of each of them leads to increased sensitivity toward oxidative stress along with mitochondrial and energetic dysfunction (Dodson and Guo, 2007). Pink1 and Parkin are directly involved in the mitophagy pathway, whereas, the precise function of DJ-1 remains under discussion. Interestingly, overexpression of Pink1 and Parkin rescues the observed phenotype caused by DJ-1 deficiency, suggesting partial redundancies in the mitophagic apparatus (Irrcher et al., 2010).
Mitochondrial fission and fusion are critical events for controlled degradation of damaged mitochondria. Optic atrophy 1 (OPA1) is an inner mitochondrial membrane protein that regulates the fusion of mitochondria, together with MFN1 and MFN2. Mutation in the OPA1 gene has been observed to cause autosomal dominant optic atrophy (ADOA) often accompanied by myopathy and progressive ataxia (Yu-Wai-Man et al., 2010). Myopathy and neurodegeneration is also observed in patients with Charcot–Marie–Tooth syndrome caused by loss of the MFN2 gene (Calvo et al., 2009), underscoring the importance of mitochondrial function in muscle and brain tissues. For both diseases impaired mitophagy has been reported, suggesting that dysfunctional mitophagy may contribute to the described disease pathology (White et al., 2009; Rizzo et al., 2016; Liao et al., 2017).
Defects in Lysosomal Function
Another group of diseases that may be partial driven by deficient mitophagy, are lysosomal storage disorders, a heterogenous group of more than 60 rare monogenic diseases that are caused by defects in lysosomal function (Platt et al., 2018). Some of the most well described are Gaucher disease and Niemann–Pick type C. Gaucher disease is caused by mutations in the glucocerebrosidase (GBA) gene, encoding a lysosomal enzyme required to hydrolyze the glycolipid glucosylceramide. Patients with Gaucher disease display features in multiple organs caused by lysosomal accumulation of glucosylceramide with a subset of patients display progressive neurodegeneration. Notably, the GBA gene represents a major risk locus for inherited Parkinson’s disease supporting the idea that mitophagy is important in this disease (Goker-Alpan et al., 2004; Lwin et al., 2004). Reduced mitochondrial respiration, increased ROS production and increased alpha-synuclein accumulation can be observed in various GBA deficiency models, cellular changes that are also described to be central drivers of neuronal loss in Parkinson’s disease (Osellame et al., 2013; Chen et al., 2019). Nieman Pick type C is caused by mutations in the NPC1 gene and is characterized by developmental delay, progressive neurodegeneration, dysphagia and vertical gaze palsy, a combination of phenotypes that can also be observed in mitochondrial disorders. In patient-derived fibroblast cells and NPC1-deficient neuronal cells impaired autophagy and an accumulation of mitochondrial fragments have been observed upon lysosomal cholesterol accumulation (Pacheco et al., 2007; Elrick et al., 2012; Ordonez et al., 2012).
Secondary Defects in Mitophagy
In addition to diseases with primary defects in mitophagy, several diseases have been described with secondary mitophagic dysfunction. In the context of monogenic diseases displaying premature aging, loss of mitophagy was first described in Cockayne syndrome, a disease characterized by progressive neurodegeneration reminiscent of mitochondrial disorders (Scheibye-Knudsen et al., 2012). The pathogenesis likely involves dysregulation of uncoupling proteins (U) due to decreased activity of the PGC-1alpha transcription factor. UCPs regulate mitochondrial membrane potential and consequently a reduction in UCPs lead to increased mitochondrial membrane potential and loss of PINK1 mediated mitophagy. Accordingly, overexpression of UCP2 can rescue mitochondrial and mitophagic defects in Cockayne syndrome. Notably, the same pathogenesis is found in related DNA repair disorders xeroderma pigmentosum group A and ataxia-telangiectasia (Fang et al., 2014, 2016).
Another disease that is characterized by mitochondrial deficiency is Zellweger syndrome, which belongs to a subgroup of peroxisome biogenesis disorders (Salpietro et al., 2015). Zellweger syndrome is caused by mutations in one of 14 human PEX genes, encoding for peroxin proteins that are required for the maintenance of peroxisomes (Waterham and Ebberink, 2012). Zellweger syndrome patients show dysmorphic features and suffer from severe neurological symptoms. Recently, PEX13 was shown to be required for mitophagy, but interestingly, dispensable for starvation-induced autophagy (Lee et al., 2017). Similarly, PEX5, an interaction partner of PEX13, has been shown to modulate autophagy via regulation of the mTOR signaling pathway (Eun et al., 2018), in line with this, mitochondrial defects can be observed in PEX5 knockout models (Baumgart et al., 2001). However, it is still unclear, to what extent the clinical features of Zellweger syndrome are driven by mitophagic defects.
Is Mitophagy a Therapeutic Target?
An increasing number of human diseases have been associated with impaired mitophagy, thus, interventions that modulate mitophagy may provide the possibility of counteracting disease development or progression (Figure 3). In recent years, multiple small molecules as well as lifestyle interventions have been shown to modulate autophagy, thereby causing health- and lifespan benefits in different organisms (Galluzzi et al., 2017). Due to the dependency on core autophagy regulators, mitophagy is modulated by most of the classic autophagy inducers such as the mTOR inhibitor rapamycin, the AMP-activated protein kinase (AMPK) activator AICAR as well as caloric restriction and exercise. In particular, the effectiveness of rapamycin and rapalogs has been intensively studied in the context of lifespan regulation and human disease development and rapamycin remain the most well documented compound for life- and healthspan extension in laboratory animals (Saxton and Sabatini, 2017). Further connections between longevity and mitophagy comes from work on the metabolite NAD+ and the NAD+-dependent acetylase Sirtuin 1 (SIRT1). Here, it has been shown that stimulation of SIRT1 through NAD+ augmentation or small molecules leads to activation of the energy responsive kinase AMPK that in turns regulates a central autophagy regulator, Unc-51-like kinase 1 (ULK1) (Egan et al., 2011; Price et al., 2012). Further, SIRT1 and AMPK also regulate the transcription factor PGC-1alpha, a key regulator of mitochondrial function that was initially found to control UCP levels and thereby mitochondrial membrane potential (Puigserver et al., 1998; Cantó et al., 2009). Indeed, SIRT1 activation leads to UCP-2 upregulation, stimulation of mitophagy and rescue of aging features in models of premature aging (Fang et al., 2014; Scheibye-Knudsen et al., 2014). Notably, direct stimulation of AMPK through the AMP-mimetic compound AICAR regulates mitochondrial dynamics via the induction of mitochondrial fission, further highlighting the broad effect of AMPK on mitochondrial function (Toyama et al., 2016).
FIGURE 3
Due to their great diversity, natural compounds are a tremendous source for novel mitophagy modulators. Urolithin A, a gut metabolite of ellagic acid, extends health- and lifespan in C. elegans as well as improving muscle function in rodent models via the induction of mitophagy (Ryu et al., 2016). The effectiveness of urolithin A was further highlighted in animal models of Alzheimer’s disease, where the disease pathology was ameliorated in the group of urolithin A-treated mice (Fang et al., 2019). In a human clinical trial study, the safety of urolithin A was evaluated, and signatures of improved mitochondrial function were demonstrated (Andreux et al., 2019). Similar to Urolithin A, the potency of antibacterial compound actinonin was demonstrated in Alzheimer’s disease models (Fang et al., 2019). Actinonin inhibits mitochondrial translation, thereby inducing mitophagy via the activation of the PINK1/Parkin-regulated signaling pathway (Richter et al., 2013; Sun et al., 2015; Burman et al., 2017). Another natural compound that has been suggested as a potential intervention for aging and diseases is the polyamine spermidine (Eisenberg et al., 2009; Madeo et al., 2018; Schwarz et al., 2018). The administration of spermidine leads to an induction of mitophagy in cardiomyocytes, along with cardio protection in mice (Eisenberg et al., 2016). The induction of autophagy via spermidine has been associated, among others, with the inhibition of the acetyltransferase EP300 and the ATM-driven activation of the PINK1/Parkin-regulated mitophagy pathway (Pietrocola et al., 2015; Qi et al., 2016).
Transcriptional regulation of mitophagy has also been shown as a viable pathway for increased mitochondrial health. An example is the synthetic compound PMI that stimulates mitophagy via the activation of the transcription factor Nrf2, which controls the expression of mitophagy genes including p62 (East et al., 2014; Bertrand et al., 2015). PMI treatment facilitates LC3 recruitment and mitochondrial ubiquitination in a PINK1/Parkin-independent manner, notably without disrupting the mitochondrial membrane potential (East et al., 2014).
Besides targeting mitophagy core proteins, intervention strategies targeting mitochondrial proteins may present a useful approach for disorders that are characterized by abnormal mitochondrial dynamic. Mdivi-1, has been identified in a yeast screen for mitochondrial fission inhibitors and several studies indicate its therapeutic potential for the treatment of neurological disorders (Cassidy-Stone et al., 2008; Cui et al., 2010; Solesio et al., 2012). However, the specificity of Mdivi-1 toward its putative target Drp1 has recently been questioned and needs to be further clarified (Bordt et al., 2017). USP30, a deubiquitinase that targets mitochondrial proteins, may present another promising target to facilitate mitophagy, since improved mitochondrial function was obtained upon USP30 depletion in different Parkinson’s disease models (Bingol et al., 2014). Notably, MF-094 has been recently identified as a selective inhibitor of USP30 that may thereby facilitate mitophagy through increased ubiquitination of outer membrane proteins (Kluge et al., 2018). Thus, a number of mitophagy modulators have been identified, yet the main goal will be the precise and specific targeting of damaged mitochondria. One possible way is to apply chimeric molecules such as the recently generated autophagy-targeting chimeric molecule (AUTAC4) that selectively targets the mitochondrial membrane for ubiquitination and subsequent degradation (Takahashi et al., 2019). These approaches may be particularly efficacious in conditions of mitophaging where the mitophagy apparatus is likely intact but mitophagy occurs at suboptimal levels.
In diseases characterized by dysfunctional lysosomes, stimulation of mitophagy may be detrimental due to an accumulation of undigested cargo material. In this regard, the inhibition of mitophagy is considered as a therapeutic strategy. In a mouse model of Pompe disease autophagy inhibition next to an enzyme replacement therapy has been proposed as a potential intervention (Raben et al., 2010). In line with this, knockdown of the mTOR pathway inhibitor TSC2 in muscle of Pompe disease mice reduced accumulation of autophagy markers and a decline in muscle atrophy was osberved (Lim et al., 2017). However, strategies to facilitate the fusion of autophagosomes and lysosomes in lysosomal storage disorders are also proposed for the treatment of several lysosomal storage disorders (Spampanato et al., 2013; Bartolomeo et al., 2017). TFEB, which controls the expression of autophagy as well as lysosomal genes and longevity (Napolitano and Ballabio, 2016), may provide a promising target since its agonists, such as the clinically approved cardiac drug digoxin or the natural compound ikarugamycin, improve metabolic function in mice and extend lifespan in C. elegans (Wang et al., 2017). The therapeutic potential of TFEB in Parkinson’s disease was further highlighted by a recent study that showed restored TFEB and improved neurological function upon rapamycin treatment in Q311X mutant parkin mice independently of the parkin E3 ligase (Siddiqui et al., 2015).
In summary, great progress has been made in recent years, however, the clinical safety of mitophagy modulating drugs needs to be further clarified. More refined tools that allow the distinction between mitophagy and general macroautophagy may be beneficial and could accelerate future discoveries. Altogether, this will enable us to step closer toward clinical validation of mitophagy modulators.
Concluding Remarks
Mitophagy is emerging as a central process preserving organismal and, especially, neurological health. Since most trials targeting age-associated neurodegeneration in the last decades have been disappointing, new pharmaceutical avenues are direly needed. Here, mitophagy stimulators could play a key role. Indeed, several clinical trials are underway testing the efficacy of mitophagy modulating compounds and the outcome of these studies will undoubtedly prove critical for the future translatability of the field. Nonetheless, the regulatory mechanism of mitophagy and its contribution to age-associated diseases still remains elusive and potential issues with artificially augmenting mitophagy have not been considered. However, given the central role of mitophaging in multiple age-related pathologies it appears highly likely that these new promising approaches may present possible interventions in age-associated diseases. The future is bright!
Statements
Author contributions
DB and MS-K wrote the manuscript and made the figures.
Funding
DB is supported by the German Research Foundation (Forschungsstipendium; BA 6276/1-1) and the Lundbeck foundation (# R303-2018-3159). MS-K is funded through the Nordea Foundation (#02-2017-1749), the Novo Nordisk Foundation (#NNF17OC0027812), the Danish Cancer Society (#R167-A11015_001), the Independent Research Fund Denmark (#7016-00230B), the Neye Foundation, the Lundbeck Foundation (#R324-2019-1492) and Insilico Medicine.
Acknowledgments
We would like to express our deep gratitude to Dr. Brenna Osborne for her critical comments to our manuscript.
Conflict of interest
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling Editor declared a past collaboration with one of the authors, MS-K.
References
1
AndingA. L.WangC.ChangT.-K.SliterD. A.PowersC. M.HofmannK.et al (2018). Vps13D encodes a ubiquitin-binding protein that is required for the regulation of mitochondrial size and clearance.Curr. Biol. CB28:287–295.e6. 10.1016/j.cub.2017.11.064
2
AndreassenS. N.Ben EzraM.Scheibye-KnudsenM. (2019). A defined human aging phenome.Aging115786–5806. 10.18632/aging.102166
3
AndreuxP. A.Blanco-BoseW.RyuD.BurdetF.IbbersonM.AebischerP.et al (2019). The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans.Nat. Metab.1595–603. 10.1038/s42255-019-0073-4
4
AparicioR.RanaA.WalkerD. W. (2019). Upregulation of the autophagy adaptor p62/SQSTM1 prolongs health and lifespan in middle-aged drosophila.Cell Rep.28:1029–1040.e5. 10.1016/j.celrep.2019.06.070
5
BakulaD.MüllerA. J.ZulegerT.TakacsZ.Franz-WachtelM.ThostA.-K.et al (2017). WIPI3 and WIPI4 β-propellers are scaffolds for LKB1-AMPK-TSC signalling circuits in the control of autophagy.Nat. Commun.8:15637. 10.1038/ncomms15637
6
BartolomeoR.CinqueL.De LeonibusC.ForresterA.SalzanoA. C.MonfregolaJ.et al (2017). mTORC1 hyperactivation arrests bone growth in lysosomal storage disorders by suppressing autophagy.J. Clin. Invest.1273717–3729. 10.1172/JCI94130
7
BaumgartE.VanhorebeekI.GrabenbauerM.BorgersM.DeclercqP. E.FahimiH. D.et al (2001). Mitochondrial alterations caused by defective peroxisomal biogenesis in a mouse model for Zellweger syndrome (PEX5 knockout mouse).Am. J. Pathol.1591477–1494. 10.1016/S0002-9440(10)62534-5
8
BernardiniJ. P.BrouwerJ. M.TanI. K.SandowJ. J.HuangS.StaffordC. A.et al (2019). Parkin inhibits BAK and BAX apoptotic function by distinct mechanisms during mitophagy.EMBO J.38:e99916. 10.15252/embj.201899916
9
BernardiniJ. P.LazarouM.DewsonG. (2017). Parkin and mitophagy in cancer.Oncogene361315–1327. 10.1038/onc.2016.302
10
BertrandH. C.SchaapM.BairdL.GeorgakopoulosN. D.FowkesA.ThiollierC.et al (2015). Design, synthesis, and evaluation of triazole derivatives that induce Nrf2 dependent gene products and inhibit the Keap1-Nrf2 protein-protein interaction.J. Med. Chem.587186–7194. 10.1021/acs.jmedchem.5b00602
11
BingolB.TeaJ. S.PhuL.ReicheltM.BakalarskiC. E.SongQ.et al (2014). The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy.Nature510370–375. 10.1038/nature13418
12
BordtE. A.ClercP.RoelofsB. A.SaladinoA. J.TretterL.Adam-ViziV.et al (2017). The putative Drp1 inhibitor mdivi-1 is a reversible mitochondrial complex I inhibitor that modulates reactive oxygen species.Dev. Cell40:583–594.e6. 10.1016/j.devcel.2017.02.020
13
BoseA.BealM. F. (2016). Mitochondrial dysfunction in Parkinson’s disease.J. Neurochem.139(Suppl. 1), 216–231. 10.1111/jnc.13731
14
BoumanL.SchlierfA.LutzA. K.ShanJ.DeinleinA.KastJ.et al (2011). Parkin is transcriptionally regulated by ATF4: evidence for an interconnection between mitochondrial stress and ER stress.Cell Death. Differ18769–782. 10.1038/cdd.2010.142
15
BradshawT. Y.RomanoL. E. L.DuncanE. J.NethisingheS.AbetiR.MichaelG. J.et al (2016). A reduction in Drp1-mediated fission compromises mitochondrial health in autosomal recessive spastic ataxia of Charlevoix Saguenay.Hum. Mol. Genet.253232–3244. 10.1093/hmg/ddw173
16
Bravo-San PedroJ. M.KroemerG.GalluzziL. (2017). Autophagy and mitophagy in cardiovascular disease.Circ. Res.1201812–1824. 10.1161/CIRCRESAHA.117.311082
17
BurmanJ. L.PicklesS.WangC.SekineS.VargasJ. N. S.ZhangZ.et al (2017). Mitochondrial fission facilitates the selective mitophagy of protein aggregates.J. Cell Biol.2163231–3247. 10.1083/jcb.201612106
18
CagalinecM.LiivM.HodurovaZ.HickeyM. A.VaarmannA.MandelM.et al (2016). Role of mitochondrial dynamics in neuronal development: mechanism for wolfram syndrome.PLoS Biol.14:e1002511. 10.1371/journal.pbio.1002511
19
CalvoJ.FunalotB.OuvrierR. A.LazaroL.ToutainA.De MasP.et al (2009). Genotype-phenotype correlations in Charcot-Marie-Tooth disease type 2 caused by mitofusin 2 mutations.Arch. Neurol.661511–1516. 10.1001/archneurol.2009.284
20
CalvoS. E.ComptonA. G.HershmanS. G.LimS. C.LieberD. S.TuckerE. J.et al (2012). Molecular diagnosis of infantile mitochondrial disease with targeted next-generation sequencing.Sci. Transl. Med.4:118ra10. 10.1126/scitranslmed.3003310
21
CantóC.Gerhart-HinesZ.FeigeJ. N.LagougeM.NoriegaL.MilneJ. C.et al (2009). AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity.Nature4581056–1060. 10.1038/nature07813
22
Cassidy-StoneA.ChipukJ. E.IngermanE.SongC.YooC.KuwanaT.et al (2008). Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax/Bak-dependent mitochondrial outer membrane permeabilization.Dev. Cell14193–204. 10.1016/j.devcel.2007.11.019
23
ChenC.TurnbullD. M.ReeveA. K. (2019). Mitochondrial dysfunction in Parkinson’s disease-cause or consequence?Biology8:20038. 10.3390/biology8020038
24
ChenM.ChenZ.WangY.TanZ.ZhuC.LiY.et al (2016). Mitophagy receptor FUNDC1 regulates mitochondrial dynamics and mitophagy.Autophagy12689–702. 10.1080/15548627.2016.1151580
25
ChenY.DornG. W. (2013). PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria.Science340471–475. 10.1126/science.1231031
26
ChenY.LiuY.DornG. W. (2011). Mitochondrial fusion is essential for organelle function and cardiac homeostasis.Circ. Res.1091327–1331. 10.1161/CIRCRESAHA.111.258723
27
ChévrierM.BrakchN.CélineL.GentyD.RamdaniY.MollS.et al (2010). Autophagosome maturation is impaired in Fabry disease.Autophagy6589–599. 10.4161/auto.6.5.11943
28
CirulliE. T.LasseigneB. N.PetrovskiS.SappP. C.DionP. A.LeblondC. S.et al (2015). Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways.Science3471436–1441. 10.1126/science.aaa3650
29
Corral-DebrinskiM.HortonT.LottM. T.ShoffnerJ. M.Flint BealM.WallaceD. C. (1992). Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age.Nat. Genet.2324–329. 10.1038/ng1292-324
30
CortopassiG. A.ArnheimN. (1990). Detection of a specific mitochondrial DNA deletion in tissues of older humans.Nucleic Acids Res.186927–6933. 10.1093/nar/18.23.6927
31
CuiH.LiF.ChenD.WangG.TruongC. K.EnnsG. M.et al (2013). Comprehensive next-generation sequence analyses of the entire mitochondrial genome reveal new insights into the molecular diagnosis of mitochondrial DNA disorders.Genet. Med. Off. J. Am. Coll. Med. Genet.15388–394. 10.1038/gim.2012.144
32
CuiM.TangX.ChristianW. V.YoonY.TieuK. (2010). Perturbations in mitochondrial dynamics induced by human mutant PINK1 can be rescued by the mitochondrial division inhibitor mdivi-1.J. Biol. Chem.28511740–11752. 10.1074/jbc.M109.066662
33
CullupT.KhoA. L.Dionisi-ViciC.BrandmeierB.SmithF.UrryZ.et al (2013). Recessive mutations in EPG5 cause Vici syndrome, a multisystem disorder with defective autophagy.Nat. Genet.4583–87. 10.1038/ng.2497
34
De DuveC.WattiauxR. (1966). Functions of lysosomes.Annu. Rev. Physiol.28435–492. 10.1146/annurev.ph.28.030166.002251
35
DeasE.Plun-FavreauH.GandhiS.DesmondH.KjaerS.LohS. H. Y.et al (2011). PINK1 cleavage at position A103 by the mitochondrial protease PARL.Hum. Mol. Genet.20867–879. 10.1093/hmg/ddq526
36
Del GrossoA.AngellaL.TonazziniI.MoscardiniA.GiordanoN.CaleoM.et al (2019). Dysregulated autophagy as a new aspect of the molecular pathogenesis of Krabbe disease.Neurobiol. Dis.129195–207. 10.1016/j.nbd.2019.05.011
37
DentonK.MouY.XuC.-C.ShahD.ChangJ.BlackstoneC.et al (2018). Impaired mitochondrial dynamics underlie axonal defects in hereditary spastic paraplegias.Hum. Mol. Genet.272517–2530. 10.1093/hmg/ddy156
38
Di RitaA.PeschiaroliA.AcunzoP. D.StrobbeD.HuZ.GruberJ.et al (2018). HUWE1 E3 ligase promotes PINK1/PARKIN-independent mitophagy by regulating AMBRA1 activation via IKKα.Nat. Commun.9:3755. 10.1038/s41467-018-05722-3
39
DodsonM. W.GuoM. (2007). Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson’s disease.Curr. Opin. Neurobiol.17331–337. 10.1016/j.conb.2007.04.010
40
DooleyH. C.RaziM.PolsonH. E. J.GirardinS. E.WilsonM. I.ToozeS. A. (2014). WIPI2 links LC3 conjugation with PI3P, autophagosome formation, and pathogen clearance by recruiting Atg12-5-16L1.Mol. Cell55238–252. 10.1016/j.molcel.2014.05.021
41
DrummondM. J.AddisonO.BrunkerL.HopkinsP. N.McClainD. A.LaStayoP. C.et al (2014). Downregulation of E3 ubiquitin ligases and mitophagy-related genes in skeletal muscle of physically inactive, frail older women: a cross-sectional comparison.J. Gerontol. A. Biol. Sci. Med. Sci.691040–1048. 10.1093/gerona/glu004
42
EastD. A.FagianiF.CrosbyJ.GeorgakopoulosN. D.BertrandH.SchaapM.et al (2014). PMI: a ΔΨm independent pharmacological regulator of mitophagy.Chem. Biol.211585–1596. 10.1016/j.chembiol.2014.09.019
43
EganD. F.ShackelfordD. B.MihaylovaM. M.GelinoS.KohnzR. A.MairW.et al (2011). Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy.Science331456–461. 10.1126/science.1196371
44
EidN.ItoY.HoribeA.OtsukiY.KondoY. (2019). Ethanol-induced mitochondrial damage in sertoli cells is associated with parkin overexpression and activation of mitophagy.Cells8:30283. 10.3390/cells8030283
45
EisenbergT.AbdellatifM.SchroederS.PrimessnigU.StekovicS.PendlT.et al (2016). Cardioprotection and lifespan extension by the natural polyamine spermidine.Nat. Med.221428–1438. 10.1038/nm.4222
46
EisenbergT.KnauerH.SchauerA.BüttnerS.RuckenstuhlC.Carmona-GutierrezD.et al (2009). Induction of autophagy by spermidine promotes longevity.Nat. Cell Biol.111305–1314. 10.1038/ncb1975
47
ElrickM. J.YuT.ChungC.LiebermanA. P. (2012). Impaired proteolysis underlies autophagic dysfunction in Niemann–Pick type C disease.Hum. Mol. Genet.214876–4887. 10.1093/hmg/dds324
48
EunS. Y.LeeJ. N.NamI.-K.LiuZ.-Q.SoH.-S.ChoeS.-K.et al (2018). PEX5 regulates autophagy via the mTORC1-TFEB axis during starvation.Exp. Mol. Med.50:4. 10.1038/s12276-017-0007-8
49
FangE. F.HouY.PalikarasK.AdriaanseB. A.KerrJ. S.YangB.et al (2019). Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer’s disease.Nat. Neurosci.22401–412. 10.1038/s41593-018-0332-9
50
FangE. F.KassahunH.CroteauD. L.Scheibye-KnudsenM.MarosiK.LuH.et al (2016). NAD+ replenishment improves lifespan and healthspan in ataxia telangiectasia models via mitophagy and DNA repair.Cell Metab.24566–581. 10.1016/j.cmet.2016.09.004
51
FangE. F.Scheibye-KnudsenM.BraceL. E.KassahunH.SenGuptaT.NilsenH.et al (2014). Defective mitophagy in XPA via PARP-1 hyperactivation and NAD(+)/SIRT1 reduction.Cell157882–896. 10.1016/j.cell.2014.03.026
52
FectoF.YanJ.VemulaS. P.LiuE.YangY.ChenW.et al (2011). SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis.Arch. Neurol.681440–1446. 10.1001/archneurol.2011.250
53
FivensonE. M.LautrupS.SunN.Scheibye-KnudsenM.StevnsnerT.NilsenH.et al (2017). Mitophagy in neurodegeneration and aging.Neurochem. Int.109202–209. 10.1016/j.neuint.2017.02.007
54
FreischmidtA.WielandT.RichterB.RufW.SchaefferV.MüllerK.et al (2015). Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia.Nat. Neurosci.18631–636. 10.1038/nn.4000
55
GalluzziL.PedroJ. M. B.-S.LevineB.GreenD. R.KroemerG. (2017). Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles.Nat. Rev. Drug Discov.16487–511. 10.1038/nrd.2017.22
56
García-PratL.Martínez-VicenteM.PerdigueroE.OrtetL.Rodríguez-UbrevaJ.RebolloE.et al (2016). Autophagy maintains stemness by preventing senescence.Nature52937–42. 10.1038/nature16187
57
GeggM. E.CooperJ. M.ChauK.-Y.RojoM.SchapiraA. H. V.TaanmanJ.-W. (2010). Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy.Hum. Mol. Genet.194861–4870. 10.1093/hmg/ddq419
58
GeislerS.HolmströmK. M.SkujatD.FieselF. C.RothfussO. C.KahleP. J.et al (2010). PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1.Nat. Cell Biol.12119–131. 10.1038/ncb2012
59
Goker-AlpanO.SchiffmannR.LaMarcaM. E.NussbaumR. L.McInerney-LeoA.SidranskyE. (2004). Parkinsonism among Gaucher disease carriers.J. Med. Genet.41937–940. 10.1136/jmg.2004.024455
60
HaackT. B.HogarthP.KruerM. C.GregoryA.WielandT.SchwarzmayrT.et al (2012). Exome sequencing reveals de novo WDR45 mutations causing a phenotypically distinct, X-linked dominant form of NBIA.Am. J. Hum. Genet.911144–1149. 10.1016/j.ajhg.2012.10.019
61
HaasR. H.ParikhS.FalkM. J.SanetoR. P.WolfN. I.DarinN.et al (2007). Mitochondrial disease: a practical approach for primary care physicians.Pediatrics1201326–1333. 10.1542/peds.2007-0391
62
HaraT.NakamuraK.MatsuiM.YamamotoA.NakaharaY.Suzuki-MigishimaR.et al (2006). Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice.Nature441885–889. 10.1038/nature04724
63
HashemS. I.MurphyA. N.DivakaruniA. S.KlosM. L.NelsonB. C.GaultE. C.et al (2017). Impaired mitophagy facilitates mitochondrial damage in Danon disease.J. Mol. Cell. Cardiol.10886–94. 10.1016/j.yjmcc.2017.05.007
64
HayflickS. J.KruerM. C.GregoryA.HaackT. B.KurianM. A.HouldenH. H.et al (2013). β-Propeller protein-associated neurodegeneration: a new X-linked dominant disorder with brain iron accumulation.Brain J. Neurol.1361708–1717. 10.1093/brain/awt095
65
HerpinA.EnglbergerE.ZehnerM.WackerR.GesslerM.SchartlM. (2015). Defective autophagy through epg5 mutation results in failure to reduce germ plasm and mitochondria.FASEB J.294145–4161. 10.1096/fj.14-265462
66
HirotaY.YamashitaS.KuriharaY.JinX.AiharaM.SaigusaT.et al (2015). Mitophagy is primarily due to alternative autophagy and requires the MAPK1 and MAPK14 signaling pathways.Autophagy11332–343. 10.1080/15548627.2015.1023047
67
HondaS.ArakawaS.NishidaY.YamaguchiH.IshiiE.ShimizuS. (2014). Ulk1-mediated Atg5-independent macroautophagy mediates elimination of mitochondria from embryonic reticulocytes.Nat. Commun.5:4004. 10.1038/ncomms5004
68
HoshinoA.MitaY.OkawaY.AriyoshiM.Iwai-KanaiE.UeyamaT.et al (2013). Cytosolic p53 inhibits Parkin-mediated mitophagy and promotes mitochondrial dysfunction in the mouse heart.Nat. Commun.4:2308. 10.1038/ncomms3308
69
HoutkooperR. H.MouchiroudL.RyuD.MoullanN.KatsyubaE.KnottG.et al (2013). Mitonuclear protein imbalance as a conserved longevity mechanism.Nature497451–457. 10.1038/nature12188
70
HsuP.LiuX.ZhangJ.WangH.-G.YeJ.-M.ShiY. (2015). Cardiolipin remodeling by TAZ/tafazzin is selectively required for the initiation of mitophagy.Autophagy11643–652. 10.1080/15548627.2015.1023984
71
HudsonG.Gomez-DuranA.WilsonI. J.ChinneryP. F. (2014). Recent Mitochondrial DNA mutations increase the risk of developing common late-onset human diseases.PLoS Genet.10:e1004369. 10.1371/journal.pgen.1004369
72
IguchiM.KujuroY.OkatsuK.KoyanoF.KosakoH.KimuraM.et al (2013). Parkin-catalyzed ubiquitin-ester transfer is triggered by PINK1-dependent phosphorylation.J. Biol. Chem.28822019–22032. 10.1074/jbc.M113.467530
73
IrrcherI.AleyasinH.SeifertE. L.HewittS. J.ChhabraS.PhillipsM.et al (2010). Loss of the Parkinson’s disease-linked gene DJ-1 perturbs mitochondrial dynamics.Hum. Mol. Genet.193734–3746. 10.1093/hmg/ddq288
74
IvankovicD.ChauK.-Y.SchapiraA. H. V.GeggM. E. (2016). Mitochondrial and lysosomal biogenesis are activated following PINK1/parkin-mediated mitophagy.J. Neurochem.136388–402. 10.1111/jnc.13412
75
IvanovaM. M.ChangsilaE.IaonouC.Goker-AlpanO. (2019). Impaired autophagic and mitochondrial functions are partially restored by ERT in Gaucher and Fabry diseases.PLoS One14:e0210617. 10.1371/journal.pone.0210617
76
JelaniM.DooleyH. C.GubasA.MohamoudH. S. A.KhanM. T. M.AliZ.et al (2019). A mutation in the major autophagy gene. WIPI2, associated with global developmental abnormalities.Brain J. Neurol.1421242–1254. 10.1093/brain/awz075
77
JiC.ZhaoH.LiD.SunH.HaoJ.ChenR.et al (2019). Role of Wdr45b in maintaining neural autophagy and cognitive function.Autophagy01–11. 10.1080/15548627.2019.1632621
78
JinS. M.LazarouM.WangC.KaneL. A.NarendraD. P.YouleR. J. (2010). Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL.J. Cell Biol.191933–942. 10.1083/jcb.201008084
79
KaneL. A.LazarouM.FogelA. I.LiY.YamanoK.SarrafS. A.et al (2014). PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity.J. Cell Biol.205143–153. 10.1083/jcb.201402104
80
KauppilaT. E. S.KauppilaJ. H. K.LarssonN.-G. (2017). Mammalian mitochondria and aging: an update.Cell Metab.2557–71. 10.1016/j.cmet.2016.09.017
81
KazlauskaiteA.KondapalliC.GourlayR.CampbellD. G.RitortoM. S.HofmannK.et al (2014). Parkin is activated by PINK1-dependent phosphorylation of ubiquitin at Ser65.Biochem. J.460127–139. 10.1042/BJ20140334
82
KimM.SandfordE.GaticaD.QiuY.LiuX.ZhengY.et al (2016). Mutation in ATG5 reduces autophagy and leads to ataxia with developmental delay.eLife5:e12245. 10.7554/eLife.12245
83
KissováI.DeffieuM.ManonS.CamougrandN. (2004). Uth1p is involved in the autophagic degradation of mitochondria.J. Biol. Chem.27939068–39074. 10.1074/jbc.M406960200
84
KitadaT.AsakawaS.HattoriN.MatsumineH.YamamuraY.MinoshimaS.et al (1998). Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism.Nature392605–608. 10.1038/33416
85
KlugeA. F.LaguB. R.MaitiP.JaleelM.WebbM.MalhotraJ.et al (2018). Novel highly selective inhibitors of ubiquitin specific protease 30 (USP30) accelerate mitophagy.Bioorg. Med. Chem. Lett.282655–2659. 10.1016/j.bmcl.2018.05.013
86
KondapalliC.KazlauskaiteA.ZhangN.WoodroofH. I.CampbellD. G.GourlayR.et al (2012). PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 65.Open Biol.2:120080. 10.1098/rsob.120080
87
KoyanoF.OkatsuK.KosakoH.TamuraY.GoE.KimuraM.et al (2014). Ubiquitin is phosphorylated by PINK1 to activate parkin.Nature510162–166. 10.1038/nature13392
88
KumaA.HatanoM.MatsuiM.YamamotoA.NakayaH.YoshimoriT.et al (2004). The role of autophagy during the early neonatal starvation period.Nature4321032–1036. 10.1038/nature03029
89
LahuertaM.AguadoC.Sánchez-MartínP.SanzP.KnechtE. (2018). Degradation of altered mitochondria by autophagy is impaired in Lafora disease.FEBS J.2852071–2090. 10.1111/febs.14468
90
LampertM. A.OrogoA. M.NajorR. H.HammerlingB. C.LeonL. J.WangB. J.et al (2019). BNIP3L/NIX and FUNDC1-mediated mitophagy is required for mitochondrial network remodeling during cardiac progenitor cell differentiation.Autophagy151182–1198. 10.1080/15548627.2019.1580095
91
LazarouM.SliterD. A.KaneL. A.SarrafS. A.WangC.BurmanJ. L.et al (2015). The ubiquitin kinase PINK1 recruits autophagy receptors to induce mitophagy.Nature524309–314. 10.1038/nature14893
92
Le GuerrouéF.EckF.JungJ.StarzetzT.MittelbronnM.KaulichM.et al (2017). Autophagosomal content profiling reveals an LC3C-dependent piecemeal mitophagy pathway.Mol. Cell68:786–796.e6. 10.1016/j.molcel.2017.10.029
93
LeeM. Y.SumpterR.ZouZ.SirasanagandlaS.WeiY.MishraP.et al (2017). Peroxisomal protein PEX13 functions in selective autophagy.EMBO Rep1848–60. 10.15252/embr.201642443
94
LegatiA.ReyesA.NascaA.InvernizziF.LamanteaE.TirantiV.et al (2016). New genes and pathomechanisms in mitochondrial disorders unraveled by NGS technologies.Biochim. Biophys. Acta18571326–1335. 10.1016/j.bbabio.2016.02.022
95
LemastersJ. J. (2005). Selective mitochondrial autophagy, or mitophagy, as a targeted defense against oxidative stress, mitochondrial dysfunction, and aging.Rejuvenation Res.83–5. 10.1089/rej.2005.8.3
96
LevineB.KroemerG. (2019). Biological functions of autophagy genes: a disease perspective.Cell17611–42. 10.1016/j.cell.2018.09.048
97
LiaoC.AshleyN.DiotA.MortenK.PhadwalK.WilliamsA.et al (2017). Dysregulated mitophagy and mitochondrial organization in optic atrophy due to OPA1 mutations.Neurology88131–142. 10.1212/WNL.0000000000003491
98
LimJ.-A.LiL.ShirihaiO. S.TrudeauK. M.PuertollanoR.RabenN. (2017). Modulation of mTOR signaling as a strategy for the treatment of Pompe disease.EMBO Mol. Med.9353–370. 10.15252/emmm.201606547
99
LiuL.FengD.ChenG.ChenM.ZhengQ.SongP.et al (2012). Mitochondrial outer-membrane protein FUNDC1 mediates hypoxia-induced mitophagy in mammalian cells.Nat. Cell Biol.14177–185. 10.1038/ncb2422
100
López-OtínC.BlascoM. A.PartridgeL.SerranoM.KroemerG. (2013). The hallmarks of aging.Cell1531194–1217. 10.1016/j.cell.2013.05.039
101
LwinA.OrviskyE.Goker-AlpanO.LaMarcaM. E.SidranskyE. (2004). Glucocerebrosidase mutations in subjects with parkinsonism.Mol. Genet. Metab.8170–73. 10.1016/j.ymgme.2003.11.004
102
MadeoF.EisenbergT.PietrocolaF.KroemerG. (2018). Spermidine in health and disease.Science359:aan2788. 10.1126/science.aan2788
103
MannV. M.CooperJ. M.KrigeD.DanielS. E.SchapiraA. H.MarsdenC. D. (1992). Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson’s disease.Brain J. Neurol.115(Pt 2), 333–342. 10.1093/brain/115.2.333
104
MaruyamaH.MorinoH.ItoH.IzumiY.KatoH.WatanabeY.et al (2010). Mutations of optineurin in amyotrophic lateral sclerosis.Nature465223–226. 10.1038/nature08971
105
McLellandG.-L.SoubannierV.ChenC. X.McBrideH. M.FonE. A. (2014). Parkin and PINK1 function in a vesicular trafficking pathway regulating mitochondrial quality control.EMBO J.33282–295. 10.1002/embj.201385902
106
MeissnerC.LorenzH.WeihofenA.SelkoeD. J.LembergM. K. (2011). The mitochondrial intramembrane protease PARL cleaves human Pink1 to regulate Pink1 trafficking.J. Neurochem.117856–867. 10.1111/j.1471-4159.2011.07253.x
107
MelberA.HaynesC. M. (2018). UPRmt regulation and output: a stress response mediated by mitochondrial-nuclear communication.Cell Res28281–295. 10.1038/cr.2018.16
108
MizushimaN. (2020). The ATG conjugation systems in autophagy.Curr. Opin. Cell Biol.631–10. 10.1016/j.ceb.2019.12.001
109
MoraniF.DocciniS.SiricaR.PaternoM.PezziniF.RiccaI.et al (2019). Functional transcriptome analysis in ARSACS KO cell model reveals a role of sacsin in autophagy.Sci. Rep.9:11878. 10.1038/s41598-019-48047-x
110
MouchiroudL.HoutkooperR. H.MoullanN.KatsyubaE.RyuD.CantóC.et al (2013). The NAD(+)/sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling.Cell154430–441. 10.1016/j.cell.2013.06.016
111
MukherjeeA. B.AppuA. P.SadhukhanT.CaseyS.MondalA.ZhangZ.et al (2019). Emerging new roles of the lysosome and neuronal ceroid lipofuscinoses.Mol. Neurodegener.14:4. 10.1186/s13024-018-0300-6
112
NapoliE.SongG.PanoutsopoulosA.RiyadhM. A.KaushikG.HalmaiJ.et al (2018). Beyond autophagy: a novel role for autism-linked Wdfy3 in brain mitophagy.Sci. Rep.8:11348. 10.1038/s41598-018-29421-7
113
NapolitanoG.BallabioA. (2016). TFEB at a glance.J. Cell Sci.1292475–2481. 10.1242/jcs.146365
114
NezichC. L.WangC.FogelA. I.YouleR. J. (2015). MiT/TFE transcription factors are activated during mitophagy downstream of Parkin and Atg5.J. Cell Biol.210435–450. 10.1083/jcb.201501002
115
NovakI.KirkinV.McEwanD. G.ZhangJ.WildP.RozenknopA.et al (2010). Nix is a selective autophagy receptor for mitochondrial clearance.EMBO Rep.1145–51. 10.1038/embor.2009.256
116
OrdonezM. P.RobertsE. A.KidwellC. U.YuanS. H.PlaistedW. C.GoldsteinL. S. B. (2012). Disruption and therapeutic rescue of autophagy in a human neuronal model of Niemann Pick type C1.Hum. Mol. Genet.212651–2662. 10.1093/hmg/dds090
117
OrdureauA.SarrafS. A.DudaD. M.HeoJ.-M.JedrychowskiM. P.SviderskiyV. O.et al (2014). Quantitative proteomics reveal a feedforward mechanism for mitochondrial PARKIN translocation and ubiquitin chain synthesis.Mol. Cell56360–375. 10.1016/j.molcel.2014.09.007
118
OsellameL. D.RahimA. A.HargreavesI. P.GeggM. E.Richard-LondtA.BrandnerS.et al (2013). Mitochondria and quality control defects in a mouse model of Gaucher disease–links to Parkinson’s disease.Cell Metab.17941–953. 10.1016/j.cmet.2013.04.014
119
OtomoT.HigakiK.NanbaE.OzonoK.SakaiN. (2009). Inhibition of autophagosome formation restores mitochondrial function in mucolipidosis II and III skin fibroblasts.Mol. Genet. Metab.98393–399. 10.1016/j.ymgme.2009.07.002
120
Oz-LeviD.Ben-ZeevB.RuzzoE. K.HitomiY.GelmanA.PelakK.et al (2012). Mutation in TECPR2 reveals a role for autophagy in hereditary spastic paraparesis.Am. J. Hum. Genet.911065–1072. 10.1016/j.ajhg.2012.09.015
121
PachecoC. D.KunkelR.LiebermanA. P. (2007). Autophagy in Niemann-Pick C disease is dependent upon Beclin-1 and responsive to lipid trafficking defects.Hum. Mol. Genet.161495–1503. 10.1093/hmg/ddm100
122
PalikarasK.LionakiE.TavernarakisN. (2015). Coordination of mitophagy and mitochondrial biogenesis during ageing in C. elegans.Nature521525–528. 10.1038/nature14300
123
PalikarasK.LionakiE.TavernarakisN. (2018). Mechanisms of mitophagy in cellular homeostasis, physiology and pathology.Nat. Cell Biol.201013–1022. 10.1038/s41556-018-0176-2
124
PicklesS.VigiéP.YouleR. J. (2018). Mitophagy and Quality Control Mechanisms in Mitochondrial Maintenance.Curr. Biol. CB28R170–R185. 10.1016/j.cub.2018.01.004
125
PietrocolaF.LachkarS.EnotD. P.Niso-SantanoM.Bravo-San PedroJ. M.SicaV.et al (2015). Spermidine induces autophagy by inhibiting the acetyltransferase EP300.Cell Death. Differ.22509–516. 10.1038/cdd.2014.215
126
PlattF. M.d’AzzoA.DavidsonB. L.NeufeldE. F.TifftC. J. (2018). Lysosomal storage diseases.Nat. Rev. Dis. Primer4:27. 10.1038/s41572-018-0025-4
127
PottierC.BieniekK. F.FinchN.van de VorstM.BakerM.PerkersenR.et al (2015). Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease.Acta Neuropathol.13077–92. 10.1007/s00401-015-1436-x
128
PriceN. L.GomesA. P.LingA. J. Y.DuarteF. V.Martin-MontalvoA.NorthB. J.et al (2012). SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function.Cell Metab.15675–690. 10.1016/j.cmet.2012.04.003
129
Proikas-CezanneT.WaddellS.GaugelA.FrickeyT.LupasA.NordheimA. (2004). WIPI-1alpha (WIPI49), a member of the novel 7-bladed WIPI protein family, is aberrantly expressed in human cancer and is linked to starvation-induced autophagy.Oncogene239314–9325. 10.1038/sj.onc.1208331
130
PuigserverP.WuZ.ParkC. W.GravesR.WrightM.SpiegelmanB. M. (1998). A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis.Cell92829–839. 10.1016/s0092-8674(00)81410-5
131
QiY.QiuQ.GuX.TianY.ZhangY. (2016). ATM mediates spermidine-induced mitophagy via PINK1 and Parkin regulation in human fibroblasts.Sci. Rep.6:24700. 10.1038/srep24700
132
RabenN.SchreinerC.BaumR.TakikitaS.XuS.XieT.et al (2010). Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder–murine Pompe disease.Autophagy61078–1089. 10.4161/auto.6.8.13378
133
RabenN.WongA.RalstonE.MyerowitzR. (2012). Autophagy and mitochondria in Pompe disease: nothing is so new as what has long been forgotten.Am. J. Med. Genet. C Semin. Med. Genet.160C13–21. 10.1002/ajmg.c.31317
134
RanaA.OliveiraM. P.KhamouiA. V.AparicioR.ReraM.RossiterH. B.et al (2017). Promoting Drp1-mediated mitochondrial fission in midlife prolongs healthy lifespan of Drosophila melanogaster.Nat. Commun.8:448. 10.1038/s41467-017-00525-4
135
RanaA.ReraM.WalkerD. W. (2013). Parkin overexpression during aging reduces proteotoxicity, alters mitochondrial dynamics, and extends lifespan.Proc. Natl. Acad. Sci. U.S.A.1108638–8643. 10.1073/pnas.1216197110
136
RichterB.SliterD. A.HerhausL.StolzA.WangC.BeliP.et al (2016). Phosphorylation of OPTN by TBK1 enhances its binding to Ub chains and promotes selective autophagy of damaged mitochondria.Proc. Natl. Acad. Sci. U.S.A.1134039–4044. 10.1073/pnas.1523926113
137
RichterU.LahtinenT.MarttinenP.MyöhänenM.GrecoD.CanninoG.et al (2013). A mitochondrial ribosomal and RNA decay pathway blocks cell proliferation.Curr. Biol.23535–541. 10.1016/j.cub.2013.02.019
138
RizzoF.RonchiD.SalaniS.NizzardoM.FortunatoF.BordoniA.et al (2016). Selective mitochondrial depletion, apoptosis resistance, and increased mitophagy in human Charcot-Marie-Tooth 2A motor neurons.Hum. Mol. Genet.254266–4281. 10.1093/hmg/ddw258
139
RyanB. J.HoekS.FonE. A.Wade-MartinsR. (2015). Mitochondrial dysfunction and mitophagy in Parkinson’s: from familial to sporadic disease.Trends Biochem. Sci.40200–210. 10.1016/j.tibs.2015.02.003
140
RyuD.MouchiroudL.AndreuxP. A.KatsyubaE.MoullanN.Nicolet-Dit-FélixA. A.et al (2016). Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents.Nat. Med.22879–888. 10.1038/nm.4132
141
SafiulinaD.KuumM.ChoubeyV.GogichaishviliN.LiivJ.HickeyM. A.et al (2019). Miro proteins prime mitochondria for Parkin translocation and mitophagy.EMBO J.38:e99384. 10.15252/embj.201899384
142
SaitsuH.NishimuraT.MuramatsuK.KoderaH.KumadaS.SugaiK.et al (2013). De novo mutations in the autophagy gene WDR45 cause static encephalopathy of childhood with neurodegeneration in adulthood.Nat. Genet.45445–449. 10.1038/ng.2562
143
SalpietroV.PhadkeR.SaggarA.HargreavesI. P.YatesR.FokolorosC.et al (2015). Zellweger syndrome and secondary mitochondrial myopathy.Eur. J. Pediatr.174557–563. 10.1007/s00431-014-2431-2
144
SandovalH.ThiagarajanP.DasguptaS. K.SchumacherA.PrchalJ. T.ChenM.et al (2008). Essential role for Nix in autophagic maturation of erythroid cells.Nature454232–235. 10.1038/nature07006
145
SarrafS. A.RamanM.Guarani-PereiraV.SowaM. E.HuttlinE. L.GygiS. P.et al (2013). Landscape of the PARKIN-dependent ubiquitylome in response to mitochondrial depolarization.Nature496372–376. 10.1038/nature12043
146
SaxtonR. A.SabatiniD. M. (2017). mTOR Signaling in Growth.Metabolism, and Disease. Cell168960–976. 10.1016/j.cell.2017.02.004
147
Scheibye-KnudsenM.MitchellS. J.FangE. F.IyamaT.WardT.WangJ.et al (2014). A high-fat diet and NAD(+) activate Sirt1 to rescue premature aging in cockayne syndrome.Cell Metab.20840–855. 10.1016/j.cmet.2014.10.005
148
Scheibye-KnudsenM.RamamoorthyM.SykoraP.MaynardS.LinP.-C.MinorR. K.et al (2012). Cockayne syndrome group B protein prevents the accumulation of damaged mitochondria by promoting mitochondrial autophagy.J. Exp. Med.209855–869. 10.1084/jem.20111721
149
Scheibye-KnudsenM.Scheibye-AlsingK.CanugoviC.CroteauD. L.BohrV. A. (2013). A novel diagnostic tool reveals mitochondrial pathology in human diseases and aging.Aging5192–208. 10.18632/aging.100546
150
SchiaviA.MaglioniS.PalikarasK.ShaikA.StrappazzonF.BrinkmannV.et al (2015). Iron-starvation-induced mitophagy mediates lifespan extension upon mitochondrial stress in C. elegans.Curr. Biol. CB251810–1822. 10.1016/j.cub.2015.05.059
151
SchwarzC.StekovicS.WirthM.BensonG.RoyerP.SigristS. J.et al (2018). Safety and tolerability of spermidine supplementation in mice and older adults with subjective cognitive decline.Aging1019–33. 10.18632/aging.101354
152
SchweersR. L.ZhangJ.RandallM. S.LoydM. R.LiW.DorseyF. C.et al (2007). NIX is required for programmed mitochondrial clearance during reticulocyte maturation.Proc. Natl. Acad. Sci. U.S.A.10419500–19505. 10.1073/pnas.0708818104
153
SeiblerP.BurbullaL. F.DulovicM.ZittelS.HeineJ.SchmidtT.et al (2018). Iron overload is accompanied by mitochondrial and lysosomal dysfunction in WDR45 mutant cells.Brain1413052–3064. 10.1093/brain/awy230
154
SettembreC.FraldiA.JahreissL.SpampanatoC.VenturiC.MedinaD.et al (2008). A block of autophagy in lysosomal storage disorders.Hum. Mol. Genet.17119–129. 10.1093/hmg/ddm289
155
Shiba-FukushimaK.ImaiY.YoshidaS.IshihamaY.KanaoT.SatoS.et al (2012). PINK1-mediated phosphorylation of the Parkin ubiquitin-like domain primes mitochondrial translocation of Parkin and regulates mitophagy.Sci. Rep.2:1002. 10.1038/srep01002
156
SiddiquiA.BhaumikD.ChintaS. J.RaneA.RajagopalanS.LieuC. A.et al (2015). Mitochondrial quality control via the PGC1α-TFEB signaling pathway is compromised by parkin Q311X mutation but independently restored by rapamycin.J. Neurosci. Off. J. Soc. Neurosci.3512833–12844. 10.1523/JNEUROSCI.0109-15.2015
157
SolesioM. E.Saez-AtienzarS.JordánJ.GalindoM. F. (2012). Characterization of mitophagy in the 6-hydoxydopamine Parkinson’s disease model.Toxicol. Sci. Off. J. Soc. Toxicol.129411–420. 10.1093/toxsci/kfs218
158
SoubannierV.McLellandG.-L.ZuninoR.BraschiE.RippsteinP.FonE. A.et al (2012). A vesicular transport pathway shuttles cargo from mitochondria to lysosomes.Curr. Biol. CB22135–141. 10.1016/j.cub.2011.11.057
159
SpampanatoC.FeeneyE.LiL.CardoneM.LimJ.-A.AnnunziataF.et al (2013). Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease.EMBO Mol. Med.5691–706. 10.1002/emmm.201202176
160
StavoeA. K.GopalP. P.GubasA.ToozeS. A.HolzbaurE. L. (2019). Expression of WIPI2B counteracts age-related decline in autophagosome biogenesis in neurons.eLife8:e44219. 10.7554/eLife.44219
161
SuleimanJ.Allingham-HawkinsD.HashemM.ShamseldinH. E.AlkurayaF. S.El-HattabA. W. (2018). WDR45B-related intellectual disability, spastic quadriplegia, epilepsy, and cerebral hypoplasia: a consistent neurodevelopmental syndrome.Clin. Genet.93360–364. 10.1111/cge.13054
162
SumpterR.SirasanagandlaS.FernándezÁF.WeiY.DongX.FrancoL.et al (2016). Fanconi Anemia Proteins Function in Mitophagy and Immunity.Cell165867–881. 10.1016/j.cell.2016.04.006
163
SunN.YouleR. J.FinkelT. (2016). The mitochondrial basis of aging.Mol. Cell61654–666. 10.1016/j.molcel.2016.01.028
164
SunN.YunJ.LiuJ.MalideD.LiuC.RoviraI. I.et al (2015). Measuring In Vivo Mitophagy.Mol. Cell60685–696. 10.1016/j.molcel.2015.10.009
165
SunY.VashishtA. A.TchieuJ.WohlschlegelJ. A.DreierL. (2012). Voltage-dependent anion channels (VDACs) recruit Parkin to defective mitochondria to promote mitochondrial autophagy.J. Biol. Chem.28740652–40660. 10.1074/jbc.M112.419721
166
TakahashiD.MoriyamaJ.NakamuraT.MikiE.TakahashiE.SatoA.et al (2019). AUTACs: cargo-specific degraders using selective autophagy.Mol. Cell76:797–810.e10. 10.1016/j.molcel.2019.09.009
167
TanakaA.ClelandM. M.XuS.NarendraD. P.SuenD.-F.KarbowskiM.et al (2010). Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by Parkin.J. Cell Biol.1911367–1380. 10.1083/jcb.201007013
168
TanakaY.GuhdeG.SuterA.EskelinenE. L.HartmannD.Lüllmann-RauchR.et al (2000). Accumulation of autophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice.Nature406902–906. 10.1038/35022595
169
ToddA. M.StaveleyB. E. (2012). Expression of Pink1 with α-synuclein in the dopaminergic neurons of Drosophila leads to increases in both lifespan and healthspan.Genet. Mol. Res. GMR111497–1502. 10.4238/2012.May.21.6
170
ToyamaE. Q.HerzigS.CourchetJ.LewisT. L.LosónO. C.HellbergK.et al (2016). AMP-activated protein kinase mediates mitochondrial fission in response to energy stress.Science351275–281. 10.1126/science.aab4138
171
TrifunovicA.WredenbergA.FalkenbergM.SpelbrinkJ. N.RovioA. T.BruderC. E.et al (2004). Premature ageing in mice expressing defective mitochondrial DNA polymerase.Nature429417–423. 10.1038/nature02517
172
ValenteE. M.Abou-SleimanP. M.CaputoV.MuqitM. M. K.HarveyK.GispertS.et al (2004). Hereditary early-onset Parkinson’s disease caused by mutations in PINK1.Science3041158–1160. 10.1126/science.1096284
173
VantaggiatoC.CrimellaC.AiroldiG.PolishchukR.BonatoS.BrighinaE.et al (2013). Defective autophagy in spastizin mutated patients with hereditary spastic paraparesis type 15.Brain J. Neurol.1363119–3139. 10.1093/brain/awt227
174
WallaceD. C. (2015). Mitochondrial DNA variation in human radiation and disease.Cell16333–38. 10.1016/j.cell.2015.08.067
175
WallaceD. C. (2018). Mitochondrial genetic medicine.Nat. Genet.501642–1649. 10.1038/s41588-018-0264-z
176
WangC.NiederstrasserH.DouglasP. M.LinR.JaramilloJ.LiY.et al (2017). Small-molecule TFEB pathway agonists that ameliorate metabolic syndrome in mice and extend C. elegans lifespan.Nat. Commun.81–14. 10.1038/s41467-017-02332-3
177
WangX.WinterD.AshrafiG.SchleheJ.WongY. L.SelkoeD.et al (2011). PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility.Cell147893–906. 10.1016/j.cell.2011.10.018
178
WangZ.MiaoG.XueX.GuoX.YuanC.WangZ.et al (2016). The Vici Syndrome Protein EPG5 Is a Rab7 Effector that Determines the Fusion Specificity of Autophagosomes with Late Endosomes/Lysosomes.Mol. Cell63781–795. 10.1016/j.molcel.2016.08.021
179
WaterhamH. R.EbberinkM. S. (2012). Genetics and molecular basis of human peroxisome biogenesis disorders.Biochim. Biophys. Acta BBA Mol. Basis Dis.18221430–1441. 10.1016/j.bbadis.2012.04.006
180
WauerT.SwatekK. N.WagstaffJ. L.GladkovaC.PrunedaJ. N.MichelM. A.et al (2015). Ubiquitin Ser65 phosphorylation affects ubiquitin structure, chain assembly and hydrolysis.EMBO J.34307–325. 10.15252/embj.201489847
181
WeilR.LaplantineE.CuricS.GéninP. (2018). Role of optineurin in the mitochondrial dysfunction: potential implications in neurodegenerative diseases and Cancer.Front. Immunol.9:1243. 10.3389/fimmu.2018.01243
182
WhiteK. E.DaviesV. J.HoganV. E.PiechotaM. J.NicholsP. P.TurnbullD. M.et al (2009). OPA1 deficiency associated with increased autophagy in retinal ganglion cells in a murine model of dominant optic atrophy.Invest. Ophthalmol. Vis. Sci.502567–2571. 10.1167/iovs.08-2913
183
WongY. C.HolzbaurE. L. F. (2014). Optineurin is an autophagy receptor for damaged mitochondria in parkin-mediated mitophagy that is disrupted by an ALS-linked mutation.Proc. Natl. Acad. Sci. U.S.A.111E4439–E4448. 10.1073/pnas.1405752111
184
YamanoK.FogelA. I.WangC.van der BliekA. M.YouleR. J. (2014). Mitochondrial Rab GAPs govern autophagosome biogenesis during mitophagy.eLife3:e01612. 10.7554/eLife.01612
185
YamanoK.YouleR. J. (2013). PINK1 is degraded through the N-end rule pathway.Autophagy91758–1769. 10.4161/auto.24633
186
YouleR. J. (2019). Mitochondria-Striking a balance between host and endosymbiont.Science365:aaw9855. 10.1126/science.aaw9855
187
YouleR. J.van der BliekA. M. (2012). Mitochondrial fission, fusion, and stress.Science3371062–1065. 10.1126/science.1219855
188
Yu-Wai-ManP.GriffithsP. G.GormanG. S.LourencoC. M.WrightA. F.Auer-GrumbachM.et al (2010). Multi-system neurological disease is common in patients with OPA1 mutations.Brain J. Neurol.133771–786. 10.1093/brain/awq007
189
ZachariM.GudmundssonS. R.LiZ.ManifavaM.ShahR.SmithM.et al (2019). Selective Autophagy of Mitochondria on a Ubiquitin-Endoplasmic-Reticulum Platform.Dev. Cell50:627–643.e5. 10.1016/j.devcel.2019.06.016
190
ZhaoH.ZhaoY. G.WangX.XuL.MiaoL.FengD.et al (2013). Mice deficient in Epg5 exhibit selective neuronal vulnerability to degeneration.J. Cell Biol.200731–741. 10.1083/jcb.201211014
191
ZhaoY. G.SunL.MiaoG.JiC.ZhaoH.SunH.et al (2015). The autophagy gene Wdr45/Wipi4 regulates learning and memory function and axonal homeostasis.Autophagy11881–890. 10.1080/15548627.2015.1047127
Summary
Keywords
autophagy, mitophagy, aging, mitophaging, monogenic disorders, interventions
Citation
Bakula D and Scheibye-Knudsen M (2020) MitophAging: Mitophagy in Aging and Disease. Front. Cell Dev. Biol. 8:239. doi: 10.3389/fcell.2020.00239
Received
29 January 2020
Accepted
23 March 2020
Published
15 April 2020
Volume
8 - 2020
Edited by
Konstantinos Palikaras, Foundation for Research and Technology Hellas, Greece
Reviewed by
Nabil Eid, United Arab Emirates University, United Arab Emirates; Carsten Culmsee, University of Marburg, Germany
Updates
Copyright
© 2020 Bakula and Scheibye-Knudsen.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Daniela Bakula, bakula@sund.ku.dkMorten Scheibye-Knudsen, mscheibye@sund.ku.dk; morten@forsoegsperson.dk
This article was submitted to Cell Death and Survival, a section of the journal Frontiers in Cell and Developmental Biology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.